Mesylate Of Tyrosine Kinase Inhibitor Imatinib In The Synthesis Of New Technology

Receptor tyrosine kinase (receptor protein tyrosine kinases, RPTKs) of the extracellular ligand binding domain is the ligand is soluble or membrane-bound peptide or protein hormones, including insulin and various growth factors. This paper is to study the tyrosine kinase inhibitors imatinib mesylate in the synthesis of new technology. Imatinib mesylate was introduced by the Novartis pHarmaceutical company, trade name "Gleevec." For the treatment of chronic myeloid leukemia (CML) blast crisis, accelerated pHase or a-interferon treatment in patients with chronic pHase after failure; unresectable or metastatic malignant gastrointestinal stromal tumors patients. Imatinib mesylate reported the synthesis of a variety, but most of the synthetic route has many defects, including yield, purity, color and so more or less problematic. My predecessors in the summary, based on the new Aging, research on multiple routes, and then found a cost-effective, simple, pure and nice synthesis of the new technology. The final product was liquid and magnetic resonance imaging with standard control, confirmed as our target product. In which the color white,99.9% purity, single-complex is less than 0.1%, the indicators are better than the reference substance.